Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13R?2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology
CAR T Cell therapy has been one of the most promising therapies in other types of cancer (although a large CAR T Cell trial for leukemia was recently placed on hold due to a few treatment related deaths). Here the researchers bring it to GBMs, and shows early signs of it helping. More work needs to be done to optimize the delivery and the targets (Other researchers are using CAR T Cells targeting EGFRvIII see clinicaltrials.gov/ct2/show/NCT02664363) . This study targeted IL13Rα2, which is another good target, but neither target is presnet in 100% of tumors. Perhaps combining them would reach the majority of patients.
Posted on: 11/25/2016
Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13Rα2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology
Click HERE to return to brain tumor news headlines